Helsinn Healthcare and Zealand Pharma Sign a Partnering Agreement for ZP1846, a Novel GLP...(is an ORL-1 receptor agonist. Zealand Ph...)

Date:11/27/2008

is an ORL-1 receptor agonist. Zealand Pharma has all the rights to the drug, which is currently in Phase II clinical development. GAP-134/ZP1609; a gap junction modifier that prevents both ventricular and atrial arrhythmias in animal models. With its oral formulation, the molecule represents a novel paradigm for the potential chronic prevention of cardiac arrhythmias. US based pharmaceutical giant Wyeth Pharmaceutical is currently conducting Phase I trials in the US.

ZP1846 is useful prevention and/or treatment of an unmet medical need like chemotherapy-induced diarrhoea, which may prevent discontinuation and dose modification during cancer chemotherapy. The compound has been partnered with Helsinn.

ZP1848 is a novel paradigm for the treatment of Inflammatory Bowel Diseases (e.g. Crohn's Disease). The compound is in late preclinical development.

In addition, Zealand Pharma has a rich and broad portfolio of pre-clinical projects targeting a variety of disease areas, including osteoporosis and obesity-related diabetes.

Zealand Pharma is based in Copenhagen and has approximately 65 employees.

The Company's investors include BankInvest Biomedical Venture, LD Pensions, Dansk Erhvervsinvestering and Sunstone Capital as well as the leading international biotech investors CDC Innovation and AGF Private Equity (both in Paris) and LSP (Amsterdam).

    Contact:
    Helsinn Healthcare SA
    Roberto De Ponti, Senior Director,
    Head of Business Development & Licensing In
    Tel.: +41-91-985-21-21
    E-Mail: info-hhc@helsinn.com
    Internet:http://www.helsinn.com

    Zealand Pharma A/S
    Mogens Vang Rasmussen
    Executive Vice President
    Chief Operating Officer and Chief Financial Officer IT & Communications
    Zealand Pharma A/S
    Smedeland 26 B
    DK-
'/>"/>
SOURCE  Helsinn Healthcare SA
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 
Related biology technology :

1. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
2. Healthcare Technologies Calls for a Shareholders Meeting to Approve the Nexgen Biofuels Transaction
3. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
4. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
5. InterCure and Omron Healthcare (UK) Ltd. Announce Marketing Collaboration for Hypertension Market in United Kingdom
6. Apria Healthcare Chooses Masimo SET Pulse Oximetry for Use in the Companys Home Health Care Business
7. NuVasive to Present at Thomas Weisel Partners Healthcare Conference
8. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
9. Boston Scientific to Participate in the Bear Stearns 20th Annual Healthcare Conference
10. ADVENTRX Pharmaceuticals to Present at the 2007 Thomas Weisel Partners Healthcare Conference
11. Caliper Life Sciences Presentation at Thomas Weisel Partners Healthcare Conference to be Webcast